The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

Summary Background BRAF V600E mutation occurs in 1–2% of lung adenocarcinomas and
acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic
lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase …

Smoking cessation has reduced the incidence of lung cancer. The authors of this review
discuss recent progress in diagnostic and treatment approaches, including molecular …

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase
(ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the …

Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors …

Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–
rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience …